-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Pharmaceutical equipment refers to the mechanical equipment used for pharmaceutical production, inspection, packaging and other process purposes
.
At present, with the rapid development of China's economy and the improvement of people's living standards, China's demand for drugs continues to increase, and the development of the pharmaceutical equipment industry has begun to be accelerated.
At the same time, the market size of China's pharmaceutical equipment industry is also growing
.
According to data, the market size of China's pharmaceutical equipment industry in 2020 has reached 21.
581 billion yuan, a year-on-year increase of 7.
26%
.
The demand for equipment in the pharmaceutical industry has increased, and high-end pharmaceutical machines have become the focus of attention in the industry (Photo source: Pharmaceutical Network) The transformation in the mid-to-high-end direction will be accelerated, and it will continue to move towards the goal of accelerating the realization of import substitution
.
It is understood that in the past, the production of pharmaceutical equipment in China was mainly based on low-level and high-repetitive production of low-end pharmaceutical equipment.
However, with the rapid development of the pharmaceutical industry and the release of a series of medical reform policies such as GMP and consistency evaluation, the entire industry In recent years, the transformation and upgrading has been accelerated, and the demand and requirements for medical equipment have also changed, and the demand for high-end products is constantly expanding and increasing
.
For example, the equipment is required to be more automated and intelligent, to be more efficient and improve quality during production, to save energy and protect the environment,
etc.
According to data, in the process of accelerating the upgrading of the pharmaceutical equipment industry, the growth rate of China's high-end pharmaceutical equipment market is accelerating.
The compound growth rate from 2015 to 2019 is 18.
9%, and from 2019 to 2024, the compound growth rate is expected to be 17.
1%.
%
.
In addition, from the perspective of the market share of high-end pharmaceutical equipment, high-end equipment has also increased from 24% in 2015 to 28% in 2019
.
Following this trend, the market share of high-end pharmaceutical equipment may further increase to 32% in 2024
.
For the continuous growth of the high-end pharmaceutical equipment market, the analysis believes that this is mainly due to the continuous expansion of the demand for high-end equipment by pharmaceutical companies
.
It is reported that many pharmaceutical companies have specially purchased high-end imported equipment, such as Qilu Pharmaceutical, in order to promote the intelligentization of the high-end pharmaceutical preparation production industry
.
But in fact, this is actually inseparable from the continuous innovation of pharmaceutical machine companies in this field
.
The author has learned that the current batch of pharmaceutical machine companies that have previously deployed in the field of high-end pharmaceutical equipment have already made breakthroughs in new products and new technologies, and are constantly accelerating the import substitution of domestic high-end pharmaceutical equipment
.
For example, Canaan Technology announced a breakthrough iteration in the company's wet granulation technology last year: using a new granulation structure specially developed and designed, the one-time yield of 10-80 mesh particles is over 97%, and 10-40 mesh is 92%.
With the above particle size ratio, the production capacity can reach 700kg/h, and the particle size distribution obtained at the same time is more concentrated
.
According to its experimental results, the iterative new technology of wet granulation can significantly improve the first-time yield and production efficiency, and provide a new process solution for the wet granulation process
.
At the end of 2021, Chutian Technology also stated in the institutional survey that the company has been deploying import substitution in the high-end market of vaccine products a few years ago, and the product performance and quality have been able to meet the needs of high-end customers, thus entering the supply chain of the high-end vaccine industry.
, has been able to compete with imported equipment on the same stage
.
In general, with the continuous expansion of the pharmaceutical market's demand for high-end pharmaceutical equipment, it will attract more and more capital's attention, and enterprises will continue to enter the high-end pharmaceutical equipment market
.
The industry predicts that in the future, companies with innovative and high-tech high-end equipment can better meet the needs of the modern pharmaceutical industry, especially the biopharmaceutical industry, and gain more market opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
At present, with the rapid development of China's economy and the improvement of people's living standards, China's demand for drugs continues to increase, and the development of the pharmaceutical equipment industry has begun to be accelerated.
At the same time, the market size of China's pharmaceutical equipment industry is also growing
.
According to data, the market size of China's pharmaceutical equipment industry in 2020 has reached 21.
581 billion yuan, a year-on-year increase of 7.
26%
.
The demand for equipment in the pharmaceutical industry has increased, and high-end pharmaceutical machines have become the focus of attention in the industry (Photo source: Pharmaceutical Network) The transformation in the mid-to-high-end direction will be accelerated, and it will continue to move towards the goal of accelerating the realization of import substitution
.
It is understood that in the past, the production of pharmaceutical equipment in China was mainly based on low-level and high-repetitive production of low-end pharmaceutical equipment.
However, with the rapid development of the pharmaceutical industry and the release of a series of medical reform policies such as GMP and consistency evaluation, the entire industry In recent years, the transformation and upgrading has been accelerated, and the demand and requirements for medical equipment have also changed, and the demand for high-end products is constantly expanding and increasing
.
For example, the equipment is required to be more automated and intelligent, to be more efficient and improve quality during production, to save energy and protect the environment,
etc.
According to data, in the process of accelerating the upgrading of the pharmaceutical equipment industry, the growth rate of China's high-end pharmaceutical equipment market is accelerating.
The compound growth rate from 2015 to 2019 is 18.
9%, and from 2019 to 2024, the compound growth rate is expected to be 17.
1%.
%
.
In addition, from the perspective of the market share of high-end pharmaceutical equipment, high-end equipment has also increased from 24% in 2015 to 28% in 2019
.
Following this trend, the market share of high-end pharmaceutical equipment may further increase to 32% in 2024
.
For the continuous growth of the high-end pharmaceutical equipment market, the analysis believes that this is mainly due to the continuous expansion of the demand for high-end equipment by pharmaceutical companies
.
It is reported that many pharmaceutical companies have specially purchased high-end imported equipment, such as Qilu Pharmaceutical, in order to promote the intelligentization of the high-end pharmaceutical preparation production industry
.
But in fact, this is actually inseparable from the continuous innovation of pharmaceutical machine companies in this field
.
The author has learned that the current batch of pharmaceutical machine companies that have previously deployed in the field of high-end pharmaceutical equipment have already made breakthroughs in new products and new technologies, and are constantly accelerating the import substitution of domestic high-end pharmaceutical equipment
.
For example, Canaan Technology announced a breakthrough iteration in the company's wet granulation technology last year: using a new granulation structure specially developed and designed, the one-time yield of 10-80 mesh particles is over 97%, and 10-40 mesh is 92%.
With the above particle size ratio, the production capacity can reach 700kg/h, and the particle size distribution obtained at the same time is more concentrated
.
According to its experimental results, the iterative new technology of wet granulation can significantly improve the first-time yield and production efficiency, and provide a new process solution for the wet granulation process
.
At the end of 2021, Chutian Technology also stated in the institutional survey that the company has been deploying import substitution in the high-end market of vaccine products a few years ago, and the product performance and quality have been able to meet the needs of high-end customers, thus entering the supply chain of the high-end vaccine industry.
, has been able to compete with imported equipment on the same stage
.
In general, with the continuous expansion of the pharmaceutical market's demand for high-end pharmaceutical equipment, it will attract more and more capital's attention, and enterprises will continue to enter the high-end pharmaceutical equipment market
.
The industry predicts that in the future, companies with innovative and high-tech high-end equipment can better meet the needs of the modern pharmaceutical industry, especially the biopharmaceutical industry, and gain more market opportunities
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
